Skip to content

Intravitreal Injections by Nurses and Physicians Compared

Intravitreal Injections by Nurses or Physicians: a Randomized Controlled Trial Comparing Efficacy, Patient Satisfaction and Health Economy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02359149
Enrollment
328
Registered
2015-02-09
Start date
2015-03-31
Completion date
2017-03-31
Last updated
2019-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eye Diseases

Keywords

Intravitreal injections, Nurses, Physicians

Brief summary

Anti-VEGF agents are given for a variety of previously untreatable eye diseases. The last years indications for their use and consequently the number of patients needing treatment, have been increasing. Most patients require multiple injections. This has resulted in many eye departments administering thousands of injections per year, also at St Olavs University Hospital Trondheim. To cope with this increase in workload, it would be helpful if injections would be given not only by the physicians but also by the nurses. This study's objective is to compare efficiency, patient satisfaction and cost per patient of injections given by nurses and physicians.

Interventions

PROCEDUREintravitreal injections given by a nurse
PROCEDUREintravitreal injections given by a physician
PROCEDUREIntravitreal injections

Sponsors

Norwegian University of Science and Technology
CollaboratorOTHER
St. Olavs Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* referred to the eye clinic for treatment of age related macular degeneration, diabetes retinopathy or retinal vein occlusion with anti-vascular endothelium growth factor * Ability to provide written informed consent * ability to comply with study assessments for the full duration of the study

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frameDescription
change in visual acuity1 yearMean change in visual acuity from baseline to 12 months, tested on ETDRS letter chart

Secondary

MeasureTime frameDescription
incidence of ocular adverse eventsfrom baseline to 12 months
patient satisfaction12 monthsquestionnaire after the first treatment will be compared with questionnaire after 12 months

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026